Time filter

Source Type

Xiaofei M.,Tianjin Medical University | Xiaofei M.,Key Laboratory of Cancer Immunology and Biotherapy of Tianjin | Yaqin Q.,Tianjin Medical University | Yaqin Q.,Key Laboratory of Cancer Immunology and Biotherapy of Tianjin | And 8 more authors.
Chinese Journal of Cancer Biotherapy | Year: 2015

Objective: To evaluate changes in and prognostic value of CD8+ T cells in the peripheral blood of melanoma patients treated with GM-CSF modified tumor cell vaccine (GVAX). Methods: Fifty-six patients with melanoma who undement GVAX treatment in the Cancer Institute of Tianjing Medical University between October, 2007 and December, 2012 were enrolled in the study. Proportions of CD3+ lymphocytes,CD4+ T cells, CD8+ T cells, regulatory T lymphocytes (Treg), natural killer cells(NK) and dendritic cell (DC 1, DC 2) before and after GVAX vaccination treatment were detemiined by flow cytometry. The relationship between the proportion of CD8+ T cells and other immune cells with patient survival at different post-treatment time points was analyzed. Results: The proportion of CD8+ T cells in peripheral blood was significantly higher (P =0. 006) after GVAX treatment (37. 56 土 12. 16%) than that before the treatment (34. 71 土 12. 30%). GVAX treatment resulted in significant decreases in the proportion of CD4+ T cells (P =0. 017) and the ratio of CD4+/CD8+ (P = 0. 009) but showed no significant effect on the proportions of NK cells, Treg cells, DC1 and DC2 cells (P >0.05). Advanced melanoma patients with a proportion of CD8+ T cells above the mean value before vaccination had better overall survival (29. 16 months) compared with those with a lower proportion of CD8+ T cells (13. 34 months)(P=0. 012). Conclusion: GVAX can enhance the ability of CD8+T cells to induce antitumor immunity. A high proportion of CD8+T cells before GVAX vaccination is a predictor of better prognosis for patients with advanced melanoma. © 2015, Editorial office of Chinese Journal of Cancer Biotherapy. All rights reserved.

Loading Key Laboratory of Cancer Immunology and Biotherapy of Tianjin collaborators
Loading Key Laboratory of Cancer Immunology and Biotherapy of Tianjin collaborators